$1.02 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 133 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | GILEAD SCIENCES INC | $37,466,000 | +19.3% | 320,000 | 0.0% | 3.67% | +12.3% | |
| ABBV | ABBVIE INC | $27,346,000 | +14.8% | 407,000 | 0.0% | 2.68% | +8.0% | |
| ORA | ORMAT TECHNOLOGIES INC | $11,309,000 | -6.2% | 80,092 | 0.0% | 1.11% | -11.7% | |
| VRX | VALEANT PHARMACEUTICALS INTL | $10,163,000 | +11.8% | 45,750 | 0.0% | 1.00% | +5.2% | |
| NVS | NOVARTIS A Gsponsored adr | $9,834,000 | -0.3% | 100,000 | 0.0% | 0.96% | -6.2% | |
| SHPG | SHIRE PLCsponsored adr | $6,866,000 | -5.0% | 134,751 | 0.0% | 0.67% | -10.6% | |
| BMY | BRISTOL MYERS SQUIBB CO | $6,654,000 | +3.2% | 100,000 | 0.0% | 0.65% | -3.0% | |
| FOLD | AMICUS THERAPEUTICS INC | $6,368,000 | +30.1% | 450,000 | 0.0% | 0.62% | +22.4% | |
| PTC THERAPEUTICS INCcall | $2,888,000 | -20.9% | 600 | 0.0% | 0.28% | -25.5% | ||
| MEDICINES COcall | $2,861,000 | +2.1% | 1,000 | 0.0% | 0.28% | -4.1% | ||
| SNA | SNAP ON INC | $2,443,000 | +8.3% | 15,340 | 0.0% | 0.24% | +1.7% | |
| SPNS | SAPIENS INTL CORP N V | $586,000 | +26.6% | 56,420 | 0.0% | 0.06% | +18.8% | |
| LMNS | LUMENIS LTD | $0 | – | 245 | 0.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.